QuidelOrtho is expected to report Q3 2026 revenue of $732.50 million and adjusted EPS of $0.18, while the current stock price of $38.50 remains well below the consensus analyst target of $52.00. Investors are primarily focused on the company's respiratory revenue performance as the transition away from high COVID-19 testing volumes continues to weigh on year-over-year comparisons.
Management's progress on debt reduction following the Ortho merger and the commercial scaling of the Savanna molecular platform are critical themes for this quarter. Market participants are also looking for stability in the Labs and Transfusion Medicine segments to offset seasonal volatility in point-of-care testing.